Abraxane Approved for Advanced NSCLC: Now What Will That Mean?
It's been over two years since I reported the details from a positive trial for Abraxane (albumin-bound paclitaxel) as a weekly treatment combined with carboplatin and compared with standard "solvent-based" Taxol (paclitaxel) along with carboplatin. While positive for showing a 8% difference in response rate, which was the primary endpoint, it didn't show a significant difference in overall survival (OS), as revealed in the